Management of Extensively Drug-Resistant Tuberculosis in Peru: Cure Is Possible

DSpace/Manakin Repository

Management of Extensively Drug-Resistant Tuberculosis in Peru: Cure Is Possible

Citable link to this page

. . . . . .

Title: Management of Extensively Drug-Resistant Tuberculosis in Peru: Cure Is Possible
Author: Bonilla, Cesar A.; Crossa, Aldo; Jave, Hector O.; Jamanca, Ronal B.; Herrera, Cesar; Asencios, Luis; Mendoza, Alberto; Zignol, Matteo; Jaramillo, Ernesto; Mitnick, Carole Diane; Bayona, Jaime

Note: Order does not necessarily reflect citation order of authors.

Citation: Bonilla, Cesar A., Aldo Crossa, Hector O. Jave, Carole D. Mitnick, Ronal B. Jamanca, Cesar Herrera, Luis Asencios, et al. 2008. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS ONE 3(8): e2957.
Full Text & Related Files:
Abstract: Aim: To describe the incidence of extensive drug-resistant tuberculosis (XDR-TB) reported in the Peruvian National multidrug-resistant tuberculosis (MDR-TB) registry over a period of more than ten years and present the treatment outcomes for a cohort of these patients. Methods: From the Peruvian MDR-TB registry we extracted all entries that were approved for second-line anti-TB treatment between January 1997 and June of 2007 and that had Drug Susceptibility Test (DST) results indicating resistance to both rifampicin and isoniazid (i.e. MDR-TB) in addition to results for at least one fluoroquinolone and one second-line injectable (amikacin, capreomycin and kanamycin). Results: Of 1,989 confirmed MDR-TB cases with second-line DSTs, 119(6.0%) XDR-TB cases were detected between January 1997 and June of 2007. Lima and its metropolitan area account for 91% of cases, a distribution statistically similar to that of MDR-TB. A total of 43 XDR-TB cases were included in the cohort analysis, 37 of them received ITR. Of these, 17(46%) were cured, 8(22%) died and 11(30%) either failed or defaulted treatment. Of the 14 XDR-TB patients diagnosed as such before ITR treatment initiation, 10 (71%) were cured and the median conversion time was 2 months. Conclusion: In the Peruvian context, with long experience in treating MDR-TB and low HIV burden, although the overall cure rate was poor, a large proportion of XDR-TB patients can be cured if DST to second-line drugs is performed early and treatment is delivered according to the WHO Guidelines.
Published Version: doi:10.1371/journal.pone.0002957
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2495032/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4621864

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters